Coherent management of thyroid nodules that grow after being identified as benign will vary depending on their biology. Some are thyroid-stimulating hormone (TSH) regulated, so a dose of levothyroxine that reduces TSH to the lower limits of normal (subsuppression) may prevent or reverse enlargement; others are controlled by poorly understood mechanisms that must be elucidated before effective medical treatment can be designed; a few are autonomous requiring obliteration, and a very few are "missed" malignancies that should be excised.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/105072503322239970 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A radiopathomics model for predicting large-number cervical lymph node metastasis in clinical N0 papillary thyroid carcinoma.
Eur Radiol
January 2025
Department of Ultrasound, Chengdu Second People's Hospital, Chengdu, China.
Objectives: This study aimed to develop a multimodal radiopathomics model utilising preoperative ultrasound (US) and fine-needle aspiration cytology (FNAC) to predict large-number cervical lymph node metastasis (CLNM) in patients with clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).
Materials And Methods: This multicentre retrospective study included patients with PTC between October 2017 and June 2024 across seven institutions. Patients were categorised based on the presence or absence of large-number CLNM in training, validation, and external testing cohorts.
Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.
J Clin Endocrinol Metab
January 2025
Rijnstate, Dept. of Radiology and Nuclear Medicine, Arnhem, The Netherlands.
Context: Radiofrequency ablation (RFA) is used as treatment for symptomatic thyroid nodules. Factors influencing the volume reduction ratio (VRR) at 12 months are not yet fully understood.
Objective: The primary objective was evaluating the VRR at 12 months after RFA.
The natural history of cytologically low-risk indeterminate thyroid nodules.
J Clin Endocrinol Metab
January 2025
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.
Background: Thyroid nodules classified cytologically as low-risk indeterminate lesions (TIR3A) on fine-needle aspiration biopsy (FNAB) present a clinical challenge due to their uncertain malignancy risk. This single-center study aimed to evaluate the natural history of TIR3A nodules.
Materials And Methods: FNABs performed between July 2017 and December 2019 were retrospectively retrieved and patients with TIR3A nodules were evaluated at baseline and throughout a follow-up based on ultrasound (US) parameters and clinical data.
Parathyroid Adenoma at the Parapharyngeal Space Detected on 99mTc-Sestamibi SPECT/CT.
Clin Nucl Med
January 2025
From the Nuclear Medicine Unit, Department of Diagnostic and Interventional Radiology, Queen Elizabeth Hospital, Hong Kong.
A 77-year-old woman was diagnosed with primary hyperparathyroidism, and initial cervical ultrasonography found no parathyroid lesion, and she was referred to the nuclear medicine unit for dual-phase 99mTc-sestamibi (MIBI) scan. The scintigraphy unveiled heterogeneous uptake patterns across bilateral thyroid lobes, corresponding to the thyroid nodules, alongside a marked focal uptake with delayed tracer washout in the right oral region. The SPECT/CT pinpointed a MIBI-avid nodule within the right parapharyngeal space, indicative of parathyroid ectopia.
View Article and Find Full Text PDFRe: 'The quandary of the indeterminate thyroid nodule'.
Clin Radiol
December 2024
Department of Radiology, Queen Alexandra Hospital, Portsmouth, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!